Skip to main
TMCI
TMCI logo

TMCI Stock Forecast & Price Target

TMCI Analyst Ratings

Based on 5 analyst ratings
Hold
Strong Buy 20%
Buy 0%
Hold 60%
Sell 20%
Strong Sell 0%

Bulls say

Treace Medical Concepts Inc. has observed a 7.0% year-over-year increase in active surgeon users, reaching approximately 3,285, despite a decline in utilization per surgeon, which reflects the company's commitment to expanding its market presence. The potential for improved profit margins is supported by the company’s focus on boosting average selling prices (ASPs) for its products and capturing a larger share of complementary foot and ankle procedures. With an enhanced sales force driving growth and the opportunity for ancillary product sales to contribute to revenue, Treace Medical Concepts is positioned for sustainable revenue growth in the coming years.

Bears say

Treace Medical Concepts Inc. is experiencing a projected revenue decline of approximately 10% year-over-year for the fourth quarter, which is typically characterized as the "bunion season." The company's revenue guidance for fiscal year 2025 has been reduced to a range of $211-213 million, down from a prior estimate of $224-230 million, largely due to weaker elective procedure volumes and specific headwinds related to their Lapiplasty procedure. Furthermore, estimates indicate negative year-over-year growth for 2026, contributing to an expectation of the company's valuation multiple remaining flat or declining due to continued market challenges.

TMCI has been analyzed by 5 analysts, with a consensus rating of Hold. 20% of analysts recommend a Strong Buy, 0% recommend Buy, 60% suggest Holding, 20% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Treace Medical Concepts and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Treace Medical Concepts (TMCI) Forecast

Analysts have given TMCI a Hold based on their latest research and market trends.

According to 5 analysts, TMCI has a Hold consensus rating as of Dec 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.07, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.07, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Treace Medical Concepts (TMCI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.